News Release
<< Back
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues
"As the largest biopharmaceutical company founded and headquartered in the Mid-South, we understand the importance of recognizing and addressing our impact on the environment, our team members and the community," said
As noted in the report, Cumberland provided 2.43 million patient doses of its products in 2021 and safely disposed of 6,200 pounds of expired and damaged goods, following strict waste guidelines.
Additionally, the company had no marketed product recalls, no marketed products listed on the
Throughout 2021, Cumberland invested an average of
Cumberland is focused on providing prescription medications that improve the quality of care for patients and address poorly met medical needs. The company strives to create solutions that help reduce costs for healthcare providers and patients. In 2021, Cumberland covered up to 60% of patient prescription costs for its gastrointestinal products through its coupon program.
For more information and to view the company's 2021 Sustainability Report, please visit www.cumberlandpharma.com and navigate to corporate governance page within the investor relations section.
About
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Disease. More information can be found on the company's website at www.cumberlandpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-2-4m-patient-doses-delivered-no-product-recalls-no-fda-issues-in-2021--301601169.html
SOURCE
Investor Contact: Shayla Simpson, Cumberland Pharmaceuticals, (615) 255-0068; Media Contacts: Molly Aggas, Dalton Agency, (704) 641-6641